Characterization of cardiac acoustic biomarkers in patients with heart failure
Key result
Wearable cardioverter defibrillator-derived diastolic cardiac acoustic biomarkers showed greater intra-subject variability than systolic parameters in heart failure patients (>29% vs <15%, p<0.01).
Why the study?
Wearable cardioverter defibrillators can record cardiac acoustic biomarkers, but their variability, diurnal variations, and changes over time in heart failure patients needed characterization.
Design
Observational study
Authors
Discussion
Loading...
Member takes
Implication
High diastolic CAB variability advises caution in single wearable readings for HF; leaves open need for standardized protocols in validation studies.
Study Design
Type
Observational (n=1,066)
Structured PICO
P
Population
1,066 heart failure patients who had cardiac acoustic biomarker recordings from a wearable cardioverter defibrillator from March 2015 to July 2017
I
Intervention
Wearable cardioverter defibrillator (WCD) recording cardiac acoustic biomarkers
O
Outcome
Cardiac acoustic biomarker (CAB) variability, diurnal variations, and changes over time (including EMAT, EMATc, LVST, LVSTc, S3 and S4 strengths, and SDI)surrogate
Main Result
p-value: p=<0.01
Cardiac acoustic biomarkers measured via wearable cardioverter defibrillators show significant diurnal variation and decrease over the duration of wear in heart failure patients, with diastolic parameters exhibiting greater intra-subject variability than systolic parameters.
Cite This Study
Burkhoff et al. (2019) conducted an observational in Heart failure (n=1,066). Wearable cardioverter defibrillator (WCD) was evaluated on Intra-subject variability of cardiac acoustic biomarkers (p=<0.01). Wearable cardioverter defibrillator-derived diastolic cardiac acoustic biomarkers showed greater intra-subject variability than systolic parameters in heart failure patients (>29% vs <15%, p<0.01).